Aicuris is at the forefront of developing innovative therapies to protect individuals with weakened immune systems from life-threatening infections. We are addressing the growing global challenge of immunodeficiency by delivering breakthrough treatments that make a tangible difference for patients in need.
Our profound expertise and track-record of transforming scientific innovation into impactful therapies has enabled us to build a robust pipeline, including the late-stage candidate pritelivir, which targets refractory and resistant HSV infections in vulnerable patient populations.
At Aicuris, we combine deep scientific knowledge with a patient-first mindset, striving to redefine the future of infection prevention and treatment.